TNFRSF17 and Miyoshi myopathy: Higher grade 3 or higher NS event incidences were also observed in CD19-NHL (37%; 95% CI, 23–52%), CD20-ALL (28%; 95% CI, 24–32%), CD19-ALL (23%; 95% CI, 16–29%), CD22-ALL (18%; 95% CI, 15–22%), BCMA-MM (12%; 95% CI, 4–20%) and anti EGFR CAR T of solid tumors (15%; 95% CI, 10–21%) (Figure 4 and Figure A5).